Milrinone
Milrinone
Milrinone is a phosphodiesterase 3 inhibitor used primarily in the treatment of heart failure. On January 8, 2018, the United States Food and Drug Administration (FDA) designated Milrinone as an orphan drug for the treatment of right heart failure (RHF) in patients with left ventricular assist devices (LVADs). This designation highlights the drug's importance in treating a condition affecting a relatively small patient population, underscoring the commitment to advancing care for individuals with severe cardiac conditions. The Baker Heart and Diabetes Institute, known for its research and development in heart and diabetes care, manufactures and distributes Milrinone.
Pharmacology
Milrinone works by inhibiting phosphodiesterase 3 (PDE3), which increases cyclic adenosine monophosphate (cAMP) in heart muscle cells. This action leads to improved myocardial contractility and vasodilation, thereby enhancing cardiac output and reducing the symptoms of heart failure.
Therapeutic Uses
While Milrinone is used for the management of acute decompensated heart failure, its role in supporting patients with LVADs, particularly those with right heart failure, is of significant interest. The orphan drug designation by the FDA for this specific use recognizes the critical need for effective therapies in this high-risk patient group.
Administration
Milrinone can be administered intravenously for acute heart failure management, offering rapid onset of action. Its use in LVAD patients requires careful monitoring by healthcare professionals to optimize dosages and manage potential side effects effectively.
Side Effects
Common side effects associated with Milrinone include:
- Arrhythmias
- Hypotension
- Headaches
- Nausea
Development and Distribution
The Baker Heart and Diabetes Institute, with its focus on cardiovascular diseases and diabetes, oversees the development and distribution of Milrinone. The institute's involvement ensures that the drug is produced according to high-quality standards and is readily available to those in need.
See Also
External Links
| Milrinone Resources | |
|---|---|
|
 |
Resources
Frequently asked questions
Additional resources | |
|---|---|
Milrinone | |
| About WikiMD |  |
 | This Milrinone article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen
